Chemotherapy pretreatment sensitizes solid tumor-derived cell lines to V alpha 24+ NKT cell-mediated cytotoxicity

International Journal of Cancer. Journal International Du Cancer
Stephen R MattarolloAndrew J Nicol

Abstract

There is an increasing awareness of the therapeutic potential for combining immune-based therapies with chemotherapy in the treatment of malignant diseases, but few published studies evaluate possible cytotoxic synergies between chemotherapy and cytotoxic immune cells. Human V alpha 24+/V beta 11+ NKT cells are being evaluated for use in cell-based immunotherapy of malignancy because of their immune regulatory functions and potent cytotoxic potential. In this study, we evaluated the cytotoxicity of combinations of chemotherapy and NKT cells to determine whether there is a potential to combine these treatment modalities for human cancer therapy. The cytotoxicity of NKT cells was tested against solid-tumor derived cell lines NCI-H358, DLD-1, HT-29, DU-145, TSU-Pr1 and MDA-MB231, with or without prior treatment of these target cells, with a range of chemotherapy agents. Low concentrations of chemotherapeutic agents led to sensitization of cell lines to NKT-mediated cytotoxicity, with the greatest effect being observed for prostate cancer cells. Synergistic cytotoxicity occurred in an NKT cell in a dose-dependent manner. Chemotherapy agents induced upregulation of cell surface TRAIL-R2 (DR5) and Fas (CD95) expression, increasing th...Continue Reading

References

Mar 12, 1999·Annual Review of Medicine·J M Timmerman, R Levy
Apr 26, 2000·The Journal of Immunology : Official Journal of the American Association of Immunologists·T TakahashiT Juji
Sep 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·L S MetelitsaR C Seeger
Mar 1, 2002·Current Opinion in Immunology·Mark J SmythDale I Godfrey
Mar 6, 2002·The Journal of Experimental Medicine·Jenny E GumperzMichael B Brenner
Mar 7, 2002·Critical Reviews in Oncology/hematology·Randy R Brutkiewicz, Venkataraman Sriram
Apr 26, 2002·Current Opinion in Immunology·Eric VivierPascale Paul
May 7, 2002·International Journal of Cancer. Journal International Du Cancer·Andreas EvdokiouDavid M Findlay
Oct 31, 2002·Nature Immunology·Gavin P DunnRobert D Schreiber
Mar 19, 2003·Advances in Cancer Research·Mary A Markiewicz, W Martin Kast
Aug 21, 2003·The Journal of Immunology : Official Journal of the American Association of Immunologists·Seddon Y ThomasAndrew D Luster
Sep 3, 2003·Nature Reviews. Cancer·Mark E Dudley, Steven A Rosenberg
Sep 5, 2003·Cancer Immunology, Immunotherapy : CII·Alicia Terando, James J Mulé
Sep 5, 2003·International Journal of Clinical Oncology·Mamoru HaradaKyogo Itoh
Oct 23, 2003·Seminars in Oncology·Lawrence Fong, Eric J Small
Nov 7, 2003·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·R D Baird, S B Kaye
Mar 25, 2004·Nature Reviews. Immunology·Dale I GodfreyLuc Van Kaer
Jun 10, 2004·Immunology and Cell Biology·Jeremy SwannMark J Smyth
Oct 14, 2004·Clinical Prostate Cancer·Jonathan E Rosenberg, Eric J Small
May 3, 2005·Nature Reviews. Cancer·Richard A Lake, Bruce W S Robinson

❮ Previous
Next ❯

Citations

Feb 1, 2007·Cancer Immunology, Immunotherapy : CII·Stephen R MattarolloAndrew J Nicol
Sep 22, 2010·Oncogene·H J SteerB W S Robinson
May 26, 2011·Journal of Translational Medicine·Ioannis AlagkiozidisGeorge Coukos
Dec 23, 2010·Immunotherapy·Flora IovinoMatilde Todaro
Jul 11, 2014·Journal of Immunology Research·Dong-Sup ChungYong-Kil Hong
Aug 12, 2014·Nature Reviews. Immunology·Stuart P Berzins, David S Ritchie
May 16, 2009·Expert Opinion on Therapeutic Patents·Mario Milco D'EliosAmedeo Amedei
May 15, 2008·Expert Opinion on Biological Therapy·Elena AmbrosinoMasaki Terabe
Dec 18, 2015·BBA Clinical·Henrique Neves, Hang Fai Kwok
Mar 1, 2008·International Journal of Cancer. Journal International Du Cancer·Hirotake TokuyamaAndrew J Nicol
Jul 24, 2012·British Journal of Pharmacology·S FallariniG Lombardi
Oct 17, 2013·Immunology·Liboria SienaMark Gjomarkaj
Apr 12, 2014·Journal of Immunological Methods·Silke SohnTonya J Webb
Jun 4, 2020·International Journal of Molecular Sciences·Angélica Díaz-BasabeFederica Facciotti
May 21, 2009·The Journal of Immunology : Official Journal of the American Association of Immunologists·Matilde TodaroGiorgio Stassi
Jul 28, 2010·The Journal of Immunology : Official Journal of the American Association of Immunologists·Gerhard WingenderMitchell Kronenberg
Oct 3, 2019·Cancers·Duygu SagGerhard Wingender
Oct 26, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Hans J J van der VlietMark A Exley
Apr 19, 2021·Journal of Nanobiotechnology·Rafieh BagherifarYousef Javadzadeh
Aug 28, 2021·International Journal of Molecular Sciences·Masatsugu MiyashitaOsamu Ukimura

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.